[Preparation and testing of a hepatitis B vaccine (author's transl)].
Starting with 41.5 l of plasma from anti-HBe positive carriers of HBs antigen, 11,400 doses of a hepatitis B vaccine with 42 micrograms HBsAg-protein and 11,300 national units HBsAg activity per dose were obtained. After purification, HBsAg is obtained in 99% purity with a yield of more than 90% protein. A possible residual infectivity was inactivated by a diluted formalin solution. The infectivity test in chimpanzees confirmed the absence of infectious hepatitis viruses (HBV and nonA-nonB). In guinea pigs the immunogenicity of the vaccine was comparable to that of the reference preparation from the U.S. National Institute of Health. The presence of Al(OH)3 in the vaccine increased the anti-HBs titre by factors of 30-50. After vaccination with two doses 41 of 45 persons became anti-HBs positive, with three doses 42 of 45 persons developed anti-HBs. Median anti-HBs titre after the third doses: schedule I (three doses in intervals of 6 weeks) 427 mWHO-U/ml; schedule II (two doses at an interval of 4 weeks, third doses 4 months after the first doses) 1535 mWHO-U/ml. The vaccine was well tolerated. There were minor local reactions only.
D000818:Animals; D006509:Hepatitis B / Q000517:prevention & control*; D006511:Hepatitis B Antigens / Q000302:isolation & purification; D006801:Humans; D002679:Pan troglodytes; D013997:Time Factors; D014765:Viral Vaccines / Q000009:adverse effects
D006511:Hepatitis B Antigens; D014765:Viral Vaccines
Herstellung und Erprobung eines Hepatitis-B-Impfstoffes.